Elsevier assumes publication of Neoplasia and Translational Oncology journals

Elsevier has acquired Neoplasia Press Inc.

Elsevier, a world-leading provider of scientific, technical and medical information products and solutions, has announced that it has acquired Neoplasia Press Inc. and assumes publication of its flagship journals, Neoplasia and Translational Oncology. These peer-reviewed, open access journals are now published by Elsevier under the Neoplasia Press imprint.

"We are delighted to add these highly regarded, rapid publication journals to our oncology journal portfolio and to our growing list of open access journals serving the global biomedical community," commented Anne Kitson, Executive Vice President, Health and Medical Sciences Journals at Elsevier. "We look forward to working closely with the Editors-in-Chief and editorial teams to ensure the journals' continuing success and expand their already impressive communities of contributors and readers."

With a significant Impact Factor of 5.398 Neoplasia is a well-established cancer research journal that publishes the results of novel investigations in all areas of oncology research. Under the editorial leadership of Alnawaz Rehemtulla, PhD, Ruth Tuttle Freeman Research Professor and Director of the Molecular Imaging Division, Department of Radiation Oncology, University of Michigan, the journal's breadth encompasses not only the traditional disciplines of cancer research, but also emerging fields and interdisciplinary investigations. Published monthly, Neoplasia features studies describing new molecular and genetic findings relating to the neoplastic phenotype and laboratory and clinical studies demonstrating creative applications of advances in the basic sciences to risk assessment, prognostic indications, detection, diagnosis, and treatment.

Sister publication Translational Oncology was successfully launched in 2008 and publishes the results of novel research investigations that bridge the laboratory and clinical settings, including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis, and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Guided by Editor-in-Chief Theodore S. Lawrence, MD, PhD, Isadore Lampe Professor and Department Chair, Department of Radiation Oncology, University of Michigan, with a 2.558 Impact Factor, this bimontly journal publishes laboratory studies of novel therapeutic interventions as well as clinical trials that evaluate new treatment paradigms for cancer.

"The transition to Elsevier has been extremely smooth," remarked Neoplasia Press Inc. Founding Editor Brian D. Ross, PhD, Robert A. Berg MD Radiology Research Professor, University of Michigan Medical School and Prof. Rehemtulla. "We are confident that Elsevier will continue to support the journals' underlying mission of serving both the scientific and clinical communities by openly disseminating important data and ideas in cancer research to facilitate the progress of research and ultimately provide those fighting neoplastic diseases with new diagnostic, preventative, and therapeutic options."

Neoplasia and Translational Oncology are available on their own dedicated Elsevier sites as well as via ScienceDirect, Elsevier's full-text platform for the library community. Both journals are included in PubMed and PubMed Central, increasing the discoverability of their content by researchers, clinicians and other healthcare professionals worldwide.




The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Researchers identify new therapeutic approach against treatment-resistant prostate cancer